skip to main content

Lorlatinib Lipids — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateImmunotherapy & Targeted TherapyLorlatinib LipidsSCE Medical Oncology

A 55-year-old man on lorlatinib for ALK+ NSCLC develops hypercholesterolaemia (TC 9.5). What causes this?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Lorlatinib causes hyperlipidaemia in ~70-80% through hepatic lipid metabolism alteration — managed with statins ± fibrates; dose reduction generally not needed if lipids manageable

Lorlatinib: hypercholesterolaemia ~70-80%, hypertriglyceridaemia ~60%. Managed with statins + fibrates. Lipid monitoring baseline then monthly ×3 months. Dose reduction rarely needed.

Reference: BNF Lorlatinib; CROWN safety